title: Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee.
authors.forename: M D
authors.initials: MD
authors.lastname: Cheitlin
authors.forename: A M
authors.initials: AM
authors.lastname: Hutter
authors.forename: R G
authors.initials: RG
authors.lastname: Brindis
authors.forename: P
authors.initials: P
authors.lastname: Ganz
authors.forename: S
authors.initials: S
authors.lastname: Kaul
authors.forename: R O
authors.initials: RO
authors.lastname: Russell
authors.forename: R M
authors.initials: RM
authors.lastname: Zusman
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D002318:Cardiovascular Diseases / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D003075:Coitus / Q000502:physiology; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D010879:Piperazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
chemical_list: D004791:Enzyme Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases